Drug Type Small molecule drug |
Synonyms (S)-(−)-hesperidin, Cirantin, Ciratin + [5] |
Target |
Action inhibitors |
Mechanism Chk1 inhibitors(Checkpoint kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC28H34O15 |
InChIKeyQUQPHWDTPGMPEX-QJBIFVCTSA-N |
CAS Registry520-26-3 |
Start Date01 Jun 2026 |
Sponsor / Collaborator- |
Start Date22 May 2026 |
Sponsor / Collaborator |
Start Date22 Oct 2025 |
Sponsor / Collaborator |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01038 | Hesperidin | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Preclinical | India | 21 May 2026 | |
| Acute Kidney Injury | Preclinical | China | 29 Jun 2025 | |
| Alzheimer Disease | Preclinical | China | 01 Feb 2025 | |
| Coloboma of Optic Nerve | Discovery | China | 01 Jun 2023 |
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 2 | 216 | (Hesperidin 1000mg) | qxspsdxinn: Odds Ratio (OR) = 1.49 (95% CI, 0.60 - 3.69), P-Value = 0.3849 View more | - | 08 Apr 2022 | ||
Placebo (Placebo 1000mg) | |||||||
Not Applicable | 6 | siqgqwbspf(jxngmnmomk) = hyfetdsikv anbhaewjle (wnovduihfc ) View more | - | 01 Apr 2007 | |||
siqgqwbspf(jxngmnmomk) = otlvucephb anbhaewjle (wnovduihfc ) View more |







